Search

Background: Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis.Objective: To evaluate the efficacy and safety of brodalumab through 120 weeks of treatment in the AMAGINE-2 trial.Methods: Patients received ustekinumab through week 52 followed by brodalumab 210 mg every 2 weeks, continuous brodalumab 210 mg every 2 weeks, or any dose of brodalumab. Efficacy data were reported through 120 weeks by using observed data, last observation carried forward, and nonresponder imputation analyses.Results: Of patients who received brodalumab 210 mg every 2 weeks, 84.4%, 75.6%, and 61.1% achieved 75%, 90%, and 100% improvement from baseline in Psoriasis Area and Severity Index at 120 weeks (observed data analysis), respectively. Patients who received brodalumab 210 mg every 2 weeks after receiving ustekinumab through 52 weeks achieved a similar skin clearance response as patients who received continuous brodalumab 210 mg every 2 weeks. Safety through 120 weeks was comparable to that of the blinded study periods.Limitations: A large number of discontinuations toward the end of the study (31% in the final 6 months) were due to early termination and led to differences between observed data and nonresponder imputation results.Conclusions: Brodalumab is well tolerated and showed robust efficacy for more than 2 years. [ABSTRACT FROM AUTHOR]

Recently completed trials of brodalumab, apremilast, and ixekizumab have demonstrated significant improvements in the treatment of patients with plaque psoriasis when compared with placebo. Patients in these trials achieved high Psoriasis Area and Severity Index, static Physician’s Global Assessment, and Dermatology Life Quality Index response rates. These agents and tofacitinib were well tolerated. [ABSTRACT FROM PUBLISHER]